Your browser doesn't support javascript.
loading
miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer.
Cabello, Paula; Torres-Ruiz, Sandra; Adam-Artigues, Anna; Forés-Martos, Jaume; Martínez, María Teresa; Hernando, Cristina; Zazo, Sandra; Madoz-Gúrpide, Juan; Rovira, Ana; Burgués, Octavio; Rojo, Federico; Albanell, Joan; Lluch, Ana; Bermejo, Begoña; Cejalvo, Juan Miguel; Eroles, Pilar.
Afiliação
  • Cabello P; Biomedical Research Institute INCLIVA, 46010 Valencia, Spain.
  • Torres-Ruiz S; International University of Valencia-VIU, 46002 Valencia, Spain.
  • Adam-Artigues A; Biomedical Research Institute INCLIVA, 46010 Valencia, Spain.
  • Forés-Martos J; Biomedical Research Institute INCLIVA, 46010 Valencia, Spain.
  • Martínez MT; Biomedical Research Institute INCLIVA, 46010 Valencia, Spain.
  • Hernando C; Biomedical Research Institute INCLIVA, 46010 Valencia, Spain.
  • Zazo S; Department of Medical Oncology, University Clinical Hospital of Valencia, 46010 Valencia, Spain.
  • Madoz-Gúrpide J; Biomedical Research Institute INCLIVA, 46010 Valencia, Spain.
  • Rovira A; Department of Medical Oncology, University Clinical Hospital of Valencia, 46010 Valencia, Spain.
  • Burgués O; Department of Pathology, Jiménez Díaz Foundation, 28040 Madrid, Spain.
  • Rojo F; Department of Pathology, Jiménez Díaz Foundation, 28040 Madrid, Spain.
  • Albanell J; Center for Biomedical Network Research on Cancer (CIBERONC), 28040 Madrid, Spain.
  • Lluch A; Department of Medical Oncology, Hospital del Mar, 08003 Barcelona, Spain.
  • Bermejo B; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain.
  • Cejalvo JM; Biomedical Research Institute INCLIVA, 46010 Valencia, Spain.
  • Eroles P; Center for Biomedical Network Research on Cancer (CIBERONC), 28040 Madrid, Spain.
Cancers (Basel) ; 15(7)2023 Apr 04.
Article em En | MEDLINE | ID: mdl-37046799
ABSTRACT
Trastuzumab treatment has significantly improved the prognosis of HER2-positive breast cancer patients. Despite this, resistance to therapy still remains the main clinical challenge. In order to evaluate the implication of microRNAs in the trastuzumab response, we performed a microRNA array in parental and acquired trastuzumab-resistant HER2-positive breast cancer cell lines. Our results identified miR-146a-5p as the main dysregulated microRNA. Interestingly, high miR-146a-5p expression in primary tumor tissue significantly correlated with shorter disease-free survival in HER2-positive breast cancer patients. The gain- and loss-of-function of miR-146a-5p modulated the response to trastuzumab. Furthermore, the overexpression of miR-146a-5p increased migration and angiogenesis, and promoted cell cycle progression by reducing CDKN1A expression. Exosomes from trastuzumab-resistant cells showed a high level of miR-146a-5p expression compared with the parental cells. In addition, the co-culture with resistant cells' exosomes was able to decrease in sensitivity and increase the migration capacities in trastuzumab-sensitive cells, as well as angiogenesis in HUVEC-2 cells. Collectively, these data support the role of miR-146a-5p in resistance to trastuzumab, and demonstrate that it can be transferred by exosomes conferring resistance properties to other cells.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha